These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9221132)

  • 1. [Is radioiodine ablation of residual thyroid tissue indicated after an operation for differentiated thyroid cancer?].
    Chebotareva ED; Shishkina VV
    Lik Sprava; 1997; (1):118-22. PubMed ID: 9221132
    [No Abstract]   [Full Text] [Related]  

  • 2. [Radioiodine treatment of differentiated thyroid carcinomas: residual ablation].
    Konrády A
    Orv Hetil; 2002 Jun; 143(25):1557; author reply. PubMed ID: 12577410
    [No Abstract]   [Full Text] [Related]  

  • 3. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
    Logue JP; Tsang RW; Brierley JD; Simpson WJ
    Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indications for adjuvant therapy of thyroid cancer with radioiodine therapy].
    Jarzab B
    Wiad Lek; 2001; 54 Suppl 1():254-65. PubMed ID: 12182034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy.
    Bal CS; Kumar A; Chandra P; Dwivedi SN; Pant GS
    Acta Oncol; 2006; 45(8):1067-72. PubMed ID: 17118841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
    Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
    Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine therapy for papillary and follicular thyroid carcinoma.
    Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
    Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The continuous debate in literature about the usage of iodine-131 dosing for the ablation of thyroid remnants and metastases.
    De Klerk JM; Oyen WJ
    Minerva Endocrinol; 2009 Mar; 34(1):57-69. PubMed ID: 19209128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radioiodine therapy in differentiated thyroid gland carcinoma].
    Schicha H; Dietlein M
    Zentralbl Chir; 1997; 122(4):266-73. PubMed ID: 9221637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report.
    Pacini F; Schlumberger M; Harmer C; Berg GG; Cohen O; Duntas L; Jamar F; Jarzab B; Limbert E; Lind P; Reiners C; Sanchez Franco F; Smit J; Wiersinga W
    Eur J Endocrinol; 2005 Nov; 153(5):651-9. PubMed ID: 16260423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis.
    Cheng W; Ma C; Fu H; Li J; Chen S; Wu S; Wang H
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1353-60. PubMed ID: 23436920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the best strategy to treat and study patients after near-total thyroidectomy?
    Sarmiento AJ; Sarmiento FM; Sarmiento AH
    J Nucl Med; 2001 Mar; 42(3):531-3. PubMed ID: 11337535
    [No Abstract]   [Full Text] [Related]  

  • 13. Pre-ablative diagnostic whole-body scan following total thyroidectomy for well-differentiated thyroid cancer: is it necessary?
    Teoh CM; Rohaizak M; Chan KY; Jasmi AY; Fuad I
    Asian J Surg; 2005 Apr; 28(2):90-6. PubMed ID: 15851360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros.
    Ain KB
    Endocrine; 2015 Sep; 50(1):61-6. PubMed ID: 26109472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
    Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
    Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
    Terris DJ
    Head Neck; 2010 Jun; 32(6):698-9. PubMed ID: 20187017
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
    Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
    Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
    Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
    J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodine and radiotherapy in the management of thyroid cancers.
    Simpson WJ
    Otolaryngol Clin North Am; 1990 Jun; 23(3):509-21. PubMed ID: 1694984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.